Format

Send to

Choose Destination
Vasc Endovascular Surg. 2009 Oct-Nov;43(5):452-6. doi: 10.1177/1538574409335037. Epub 2009 Jul 29.

Intermittent roxithromycin for preventing progression of small abdominal aortic aneurysms: long-term results of a small clinical trial.

Author information

1
Vascular Research Unit, Department of Vascular Surgery, Viborg Hospital, Denmark. a_l_hogh@yahoo.dk

Abstract

BACKGROUND:

Antibodies against Chlamydia pneumoniae are associated with an increased rate of expansion of small abdominal aortic aneurysms (AAAs). Short-term follow-up trials have shown a transient reduction AAA growth rate, in macrolide treated compared with placebo. Therefore we analysed the influence of intermittent, long-term roxithromycin treatment on AAA expansion and referral for surgery.

METHODS:

Eighty-four patients with small AAAs were randomized to either an annual 4 weeks' treatment with roxithromycin or placebo, and followed prospectively.

RESULTS:

Intermittent, long-term Roxithromycin-treatment reduced mean annual growth rate by 36% compared with placebo after adjustment for potential confounders. Long-term roxithromycin-treated patients had a 29% lower risk of being referred for surgical evaluation, increasing to 57% after adjusting for potential confounders.

CONCLUSION:

Annual 4 week treatment with 300 mg roxithromycin daily may reduce the progression of small AAAs, and later need for surgical repair. However, more robust studies are needed for confirmation.

PMID:
19640922
DOI:
10.1177/1538574409335037
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center